Rivastigmine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Traumatic Brain Injury With Persistent Cognitive Deficits
Conditions
Traumatic Brain Injury With Persistent Cognitive Deficits
Trial Timeline
Nov 1, 2002 → Jan 1, 2005
NCT ID
NCT00219245About Rivastigmine
Rivastigmine is a approved stage product being developed by Novartis for Traumatic Brain Injury With Persistent Cognitive Deficits. The current trial status is completed. This product is registered under clinical trial identifier NCT00219245. Target conditions include Traumatic Brain Injury With Persistent Cognitive Deficits.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00000174 | Phase 3 | Completed |
| NCT02989402 | Approved | Completed |
| NCT02063269 | Pre-clinical | UNKNOWN |
| NCT00104442 | Approved | Completed |
| NCT00134953 | Phase 3 | Terminated |
| NCT00171795 | Phase 3 | Completed |
| NCT00219245 | Approved | Completed |
| NCT00130338 | Phase 3 | Completed |
| NCT00099216 | Phase 3 | Completed |
Competing Products
20 competing products in Traumatic Brain Injury With Persistent Cognitive Deficits
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product | Sun Pharmaceutical | Phase 1 | 33 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| SYN117 (nepicastat) + Placebo comparator | Johnson & Johnson | Phase 2 | 52 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 77 |
| Adjunctive asenapine | Merck | Approved | 85 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| Alendronate | Merck | Approved | 85 |
| Iloperidone + Placebo | Novartis | Phase 2 | 52 |
| AMG 334 | Novartis | Phase 2 | 52 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |
| Growth Hormone | Novo Nordisk | Phase 2 | 51 |